A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder
Phase of Trial: Phase IV
Latest Information Update: 18 May 2017
At a glance
- Drugs Levomilnacipran (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 11 May 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 19 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.